Marqeta Stock Soars 20.6% on Strong Q2 Earnings

Generated by AI AgentAinvest Pre-Market Radar
Thursday, Aug 7, 2025 7:02 am ET1min read
MQ--
Aime RobotAime Summary

- Marqeta's stock surged 20.6% pre-market on August 7, 2025, driven by Q2 results exceeding expectations.

- Revenue rose 20.1% YoY to $150.4M (vs. $140.5M estimate), with EPS at $0 vs. -$0.03 forecast.

- Adjusted EBITDA of $28.51M beat estimates by 95.5%, while Q3 guidance exceeded analyst projections.

- Despite 4.7% annual sales decline over three years, analysts project 15.8% revenue growth for the next 12 months.

Marqeta's stock surged 20.6% in pre-market trading on August 7, 2025, driven by strong second-quarter financial results that exceeded market expectations.

Marqeta reported a 20.1% year-on-year increase in revenue, reaching $150.4 million, which surpassed analyst estimates of $140.5 million. The company's earnings per share (EPS) also beat expectations, reporting $0 compared to the estimated loss of $0.03. Additionally, Marqeta's adjusted EBITDA of $28.51 million exceeded analyst estimates by 95.5%, showcasing a 19% margin.

Marqeta's guidance for the next quarter's revenue was also better than expected, with a midpoint of $148.4 million, 1.8% above analysts' estimates. However, the company's operating margin decreased to -6.1% from 83.9% in the same quarter last year, and free cash flow dropped to -$1.39 million from $8.72 million in the previous quarter.

Despite a challenging period over the past three years, where Marqeta's sales declined at a 4.7% annual rate, the company's recent performance indicates a potential turnaround. Analysts project a 15.8% revenue growth over the next 12 months, suggesting that Marqeta's newer products and services may drive better top-line performance in the future.

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet